S 822119th CongressIntroduced

Scientific EXPERT Act of 2025

Standard Summary
Balanced plain-English summary

The Scientific EXPERT Act establishes a process for science-focused drug development meetings led by the Reagan-Udall Foundation to facilitate development of treatments for rare diseases.

Key Points

  • 1Creates EL-SFDD meetings for rare disease drug development discussions
  • 2Establishes permanent multistakeholder steering committee
  • 3Requires minimum of 4 meetings annually focusing on different rare diseases
  • 4Mandates FDA review division participation in meetings
  • 5Requires public availability of meeting transcripts and summaries
  • 6Includes annual reporting and evaluation requirements

Impact Areas

Rare disease patients and advocacy groupsPharmaceutical companies developing rare disease treatmentsFDA regulatory processesAcademic researchers and medical expertsReagan-Udall Foundation
Generated by kwaipilot/kat-coder-pro:freeNov 19, 2025